A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback